Equities research analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to post sales of $100,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Xenon Pharmaceuticals’ earnings. The highest sales estimate is $180,000.00 and the lowest is $20,000.00. Xenon Pharmaceuticals posted sales of $20,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 400%. The firm is scheduled to announce its next earnings report on Tuesday, May 8th.
On average, analysts expect that Xenon Pharmaceuticals will report full year sales of $12.86 million for the current year, with estimates ranging from $12.55 million to $13.16 million. For the next financial year, analysts anticipate that the business will report sales of $10.00 million per share. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.34). Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 65.72%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $6.38 million.
A number of research analysts have recently issued reports on XENE shares. Zacks Investment Research raised Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, January 21st. ValuEngine raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Stifel Nicolaus raised their price objective on Xenon Pharmaceuticals from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Finally, Jefferies Group raised their price objective on Xenon Pharmaceuticals to $6.00 and gave the company a “buy” rating in a research note on Thursday, March 22nd. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $6.67.
NASDAQ XENE opened at $5.45 on Friday. Xenon Pharmaceuticals has a twelve month low of $2.10 and a twelve month high of $5.80. The company has a current ratio of 10.98, a quick ratio of 10.99 and a debt-to-equity ratio of 0.17. The stock has a market cap of $74.40, a price-to-earnings ratio of -3.17 and a beta of 0.74.
Large investors have recently made changes to their positions in the company. Sabby Management LLC grew its stake in shares of Xenon Pharmaceuticals by 7.1% during the fourth quarter. Sabby Management LLC now owns 329,400 shares of the biopharmaceutical company’s stock valued at $931,000 after buying an additional 21,800 shares during the last quarter. K2 Principal Fund L.P. grew its stake in shares of Xenon Pharmaceuticals by 33.5% in the fourth quarter. K2 Principal Fund L.P. now owns 219,543 shares of the biopharmaceutical company’s stock worth $620,000 after purchasing an additional 55,033 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Xenon Pharmaceuticals by 59.2% in the fourth quarter. Renaissance Technologies LLC now owns 249,000 shares of the biopharmaceutical company’s stock worth $703,000 after purchasing an additional 92,600 shares during the last quarter. 64.62% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/17/xenon-pharmaceuticals-inc-xene-expected-to-post-quarterly-sales-of-100000-00.html.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.